Product Details

Omalizumab is a recombinant humanized monoclonal antibody (IgG1) that specifically targets immunoglobulin E (IgE). As a biosimilar to the FDA-approved therapeutic omalizumab, it is designed to neutralize free IgE, preventing its interaction with FcεRI receptors on mast cells and basophils. This inhibition reduces allergic inflammation and hypersensitivity reactions. Omalizumab binds to the Fc region of circulating IgE, blocking its ability to bind to FcεRI receptors on immune cells. This prevents the activation and degranulation of mast cells and basophils, thereby reducing the release of histamine and other inflammatory mediators involved in allergic responses.